June 25, 2020 / 10:14 AM / 21 days ago

BRIEF-Theravance Announces First Patient Dosed In Phase 2 Study Of TD-0903 For Acute Lung Injury By COVID-19

June 25 (Reuters) - Theravance Biopharma Inc:

* THERAVANCE BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF TD-0903 FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY CAUSED BY COVID-19

* THERAVANCE BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF TD-0903 FOR TREATMENT OF HOSPITALIZED PATIENTS WITH ACUTE LUNG INJURY CAUSED BY COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below